Inclusion Criteria Healthy Volunteer:

• Adult 18 years of age or older
• Able to give informed consent.
• Able to comprehend and willing to follow instructions for study procedures as called for by the protocol
• Capable of lying still and supine within the PET/CT scanner for up to 75 minutes.
• No illicit drug use or other inhaled drug use (including pharmacologic agents and illicit drugs) within the past year per self-reporting mechanisms.
• No history of claustrophobia or other condition that has previously or would interfere with completion of protocol specified imaging sessions.
• Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64Cu-LLP2A) is negative.

Inclusion Criteria Hematological Malignancy:

• Clinical or pathologically defined MM or lymphoma including both newly diagnosed, relapsed or refractory disease:

  • Multiple Myeloma defined in accordance with the International Myeloma Working Group criteria
  • Low-grade lymphoma, including the following subtypes: follicular lymphoma, marginal zone lymphoma, lymphoplasmacytic lymphoma, small lymphocytic lymphoma/chronic lymphocytic leukemia

• Adult 18 years of age or older and able to provide informed consent

• Capable of lying still and supine within the PET/CT scanner for up to 75 minutes.

• No history of claustrophobia or other condition that has previously or would interfere with completion of protocol specified imaging sessions

• Not currently pregnant or nursing: Subject must be surgically sterile (has had a documented bilateral oophorectomy and/or documented hysterectomy), post-menopausal (cessation of menses for more than 1 year), non-lactating, or of childbearing potential for whom a urine pregnancy test (with the test performed within the 24 hour period immediately prior to administration of 64Cu-LLP2A) is negative

• Patients participating in imaging or therapeutic trials with investigational agents are eligible to participate